Abraham Dreazen - Nextage Therapeutics Chief Officer
| NXTG Stock | ILA 101.10 2.60 2.51% |
Insider
Abraham Dreazen is Chief Officer of Nextage Therapeutics
| Age | 39 |
| Phone | 972 73 2753450 |
| Web | https://www.nxtg.co.il/ |
Nextage Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7891) % which means that it has lost $0.7891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.4931) %, meaning that it generated substantial loss on money invested by shareholders. Nextage Therapeutics' management efficiency ratios could be used to measure how well Nextage Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Doron Cohen | Discount Investment Corp | 63 | |
| Shai Ozon | Abra Information Technologies | 53 | |
| Boaz Leshem | Scope Metals Group | 63 | |
| Yoav Chelouche | Tower Semiconductor | 66 | |
| Nava Levy | Analyst IMS Investment | ||
| Eytan Fisman | Abra Information Technologies | N/A | |
| Noam Rokach | Analyst IMS Investment | 52 | |
| Rafi Niv | Meitav Dash Investments | 60 | |
| Haim Taboch | Discount Investment Corp | 53 | |
| Iris Avner | Tower Semiconductor | 54 | |
| Eliaz Omer | Scope Metals Group | N/A | |
| Gil CPA | Scope Metals Group | 56 | |
| Gilad Fishman | Scope Metals Group | 51 | |
| Frank Cohen | Analyst IMS Investment | 46 | |
| Noit LevyKaroubi | Tower Semiconductor | 38 | |
| Itzik Schneidowski | Analyst IMS Investment | 54 | |
| Stanley ADV | Scope Metals Group | N/A | |
| Zvika CPA | Scope Metals Group | N/A | |
| Jerry Neal | Tower Semiconductor | 74 | |
| Victor Braha | Analyst IMS Investment | 49 | |
| Baruch Itzhak | Discount Investment Corp | 51 | |
Management Performance
| Return On Equity | -2.49 | |||
| Return On Asset | -0.79 |
Nextage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nextage Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.49 | |||
| Return On Asset | -0.79 | |||
| Operating Margin | 146.35 % | |||
| Current Valuation | 13.43 M | |||
| Shares Outstanding | 26.14 M | |||
| Shares Owned By Insiders | 82.36 % | |||
| Price To Book | 9.68 X | |||
| Price To Sales | 289.01 X | |||
| Revenue | 91 K | |||
| Gross Profit | 16 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.